On this Page
- What is blinding in clinical trials?
- Where is it used in clinical trials?
- How does Clinion implement it?
- What does it look like in practice?
- Related Terms
- Related Articles
- Category
What is blinding in clinical trials?
Blinding is a methodological approach used in clinical trials to prevent participants, investigators, or assessors from knowing which treatment is being administered. Its purpose is to reduce bias in data collection, assessment, and interpretation, helping ensure the trial measures the true effects of the intervention regardless of expectations or preconceptions.
Where is it used in clinical trials?
Blinding is applied in trials where awareness of treatment could influence behavior, assessments, or reporting. It can be used in any phase where bias may affect outcomes, including early-phase safety studies and late-phase efficacy trials. The technique can be implemented at different levels, such as single blinding (participants only), double blinding (participants and investigators), or triple blinding (participants, investigators, and assessors), depending on study design and regulatory requirements.
How does Clinion implement it?
Clinion enables blinding through configurable role-based access and integration with its RTSM module. The system ensures treatment allocation information is only visible to authorized roles, while blinded users can perform their tasks without exposure. Clinion also supports emergency unblinding through controlled, documented procedures and maintains a complete audit trail for all allocation-related actions to ensure compliance with regulatory standards.
What does it look like in practice?
When a subject is randomized through Clinion RTSM, the system assigns a coded treatment identifier rather than a drug name. Site users see only kit numbers or neutral labels such as treatment codes, along with clear dispensing instructions. Investigators and site staff record visits and safety data in EDC without visibility into actual treatment identities. If unblinding is required, access to the real treatment mapping is restricted to authorized roles and captured through a controlled, auditable workflow.
Category
RTSM